Skip to content

Clinical Effects of Intermitent Continuous Glucose Monitoring in Type 1 Diabetes

Clinical Effects of Intermitent Continuous Glucose Monitoring (Flash) in Adult Patients With Type 1 Diabetes in an Spanish Public Health System

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05095610
Enrollment
1121
Registered
2021-10-27
Start date
2021-11-01
Completion date
2022-05-06
Last updated
2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

type 1 diabetes, intermitent continous glucose monitoring, Flash

Brief summary

Observational cross-sectional multicenter study about clinical effect of intermitent continuous glucose monitoring (Flash) in adult type 1 diabetes patients in an Spanish public health system.

Detailed description

Observational cross-sectional multicenter study about clinical effect of intermitent continuous glucose monitoring (Flash) in adult type 1 diabetes patients in an Spanish public health system. All clinical variables are gathered from chart review. Data analysis is conducted using SPSS statistic software. Results are presented as mean +/- SD values. A paired Student´s t-test or Wilconxon signed test were used fr the analysis differences. Comparison between proportions were analyzed using a chi-square test. A P value \<0.05 was considered statistically significant. The protocolo was apporved by the reference Castilla-La Mancha Public Health Service Ethic Commitee. All participants provided written consent.

Interventions

DEVICEFlash

Use of the device FreeStyle Libre, only commercialized system for intermitent continuous glucose monitoring.

Sponsors

Castilla-La Mancha Health Service
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Presence of Type 1 diabetes. * Age \>18 years. * Patients previously followed in the DIACAM study.

Exclusion criteria

* Any other kinds of diabetes.

Design outcomes

Primary

MeasureTime frameDescription
HbA1c difference1 yearDifference in HbA1c before initiating iCGM compared with HbA1c levels after one year of treatment.

Secondary

MeasureTime frameDescription
%CV1 yearPercentage of the variation coefficient (%, \>36% is considered high levels)
Body weight1 yearTotal corporal body weight (Kg)
Insulin dose1 yearDaily insulin dose requirements (UI/Kg/d)
TBR1 yearTime bellow range (TBR, \<3.9 mmol/L) of the interstitial glucose
TIR1 yearTime in range (TIR, 3.9-10 mmol/L) of the interstitial glucose
TAR1 yearTime above range (TAR, \>10 mmol/L) of the interstitial glucose
Frequency of SBGM1 yearDaily number of blood capilary test fot glycemia determination.
Adherence to Flash1 yearTime of use of Flash glucose monitoring (% possible time of use)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026